Please assess the completion status of the following clinical trial:

Trial Title: A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* are either Male or Female at least 18 years of age~* are scheduled for radical cystectomy~* are scheduled to receive postoperative pain management with intravenous participant-controlled opioid analgesics~Exclusion Criteria:~* are scheduled for a partial cystectomy~* have taken more than 3 doses of opioids (oral or parenteral) within 7 days before the day of surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alvimopan (Type: EXPERIMENTAL): 12 milligrams (mg)~Alvimopan, 12mg, capsule. Administered orally. One 30 minutes to 5 hours before the scheduled start of surgery on Day 0, and twice daily beginning on Postoperative Day 1 (POD 1) until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment
- Placebo (Type: PLACEBO_COMPARATOR): 300 mg polyethylene glycol in a capsule~Administered orally at least 30 minutes and no later than 5 hours before the scheduled start of surgery on Day 0. On Day 1, a single dose of placebo was given twice a day for a maximum of 7 days in hospital after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).